What's Happening?
A recent webinar hosted by Genetic Engineering and Biotechnology News discussed data-driven strategies for addressing the purification challenges of bispecific antibodies (bsAbs). These antibodies, which have complex structures and assembly pathways, present unique purification challenges compared to monoclonal antibodies. The webinar highlighted issues such as mispairing, aggregation, and product instability. Experts shared strategies to improve selectivity and process robustness, including the use of ion exchange and hydrophobic interaction chromatography. These approaches aim to meet the strict regulatory expectations for clinical manufacturing of bsAbs.
Why It's Important?
Bispecific antibodies are a promising area in therapeutic development, offering potential
treatments for various diseases. However, their complex nature poses significant challenges in purification, which is critical for ensuring product safety and efficacy. The strategies discussed in the webinar are crucial for advancing the clinical manufacturing of bsAbs, potentially leading to more effective treatments. By addressing these challenges, the biopharmaceutical industry can improve the scalability and reliability of bsAb production, ultimately benefiting patients and healthcare providers.
